Case Control Study
Copyright ©The Author(s) 2021.
World J Psychiatr. Aug 19, 2021; 11(8): 449-462
Published online Aug 19, 2021. doi: 10.5498/wjp.v11.i8.449
Table 2 Patients’ clinical data, n (%)

Control group
Experimental group
χ2/Z score
P value
Cancer diagnosis4.6930.584
Breast cancer6 (14.60)4 (9.10)
Lung cancer7 (17.10)6 (13.60)
Gastrointestinal cancer7 (17.10)12 (27.30)
Nasopharyngeal cancer2 (4.90)4 (9.10)
Gynecological cancer14 (34.10)16 (36.40)
Pancreatic cancer2 (4.90)0 (0.00)
Others3 (7.30)2 (4.50)
Metastasis0.8480.357
Yes16 (39.00)13 (29.50)
No25 (61.00)31 (70.50)
Clinical manifestation status–0.02810.978
Grade 016 (40.00)9 (20.50)
Grade 17 (17.50)23 (52.30)
Grade 29 (22.50)7 (15.90)
Grade 34 (10.00)5 (11.40)
Grade 44 (10.00)0 (0.00)
Stratification5.3200.150
Asymptomatic, stable, anti-cancer6 (15.40)5 (11.40)
Asymptomatic, stable, not anti-cancer2 (5.10)1 (2.30)
Symptomatic, anti-cancer remission24 (61.50)36 (81.80)
Symptomatic, symptom control7 (17.90)2 (4.50)
Treatment16.4670.110
Palliative care7 (17.10)0 (0.00)
Radiotherapy0 (0.00)5 (11.40)
Chemotherapy28 (68.30)31 (70.50)
Hormone Therapy0 (0.00)2 (4.50)
Chemoradiotherapy6 (14.60)4 (9.10)
Others0 (0.00)2 (4.60)